Based on the key indicators related to Checkpoint Therapeutics' liquidity, profitability, solvency, and operating efficiency, Checkpoint Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Checkpoint Therapeutics' Accounts Payable is comparatively stable compared to the past year. Common Stock Total Equity is likely to gain to about 10.9 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 12.9 M in 2024. Key indicators impacting Checkpoint Therapeutics' financial strength include:
Investors should never underestimate Checkpoint Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Checkpoint Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Checkpoint Therapeutics.
Net Income
(54.44 Million)
Checkpoint
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Other Non Cash Items
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Change Receivables
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Issuance Of Capital Stock
Change To Inventory
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Retained Earnings
Accounts Payable
Cash
Net Receivables
Common Stock Total Equity
Retained Earnings Total Equity
Common Stock Shares Outstanding
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Accumulated Other Comprehensive Income
Common Stock
Net Debt
Cash And Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Net Invested Capital
Net Working Capital
Capital Stock
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Net Interest Income
Non Operating Income Net Other
Probability Of Bankruptcy
Understanding current and past Checkpoint Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Checkpoint Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Checkpoint Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Checkpoint Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Checkpoint Therapeutics. Check Checkpoint Therapeutics' Beneish M Score to see the likelihood of Checkpoint Therapeutics' management manipulating its earnings.
Checkpoint Therapeutics Stock Summary
Checkpoint Therapeutics competes with Mustang Bio, Reviva Pharmaceuticals, Fortress Biotech, Kodiak Sciences, and Fortress Biotech. Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Checkpoint Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Checkpoint Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Checkpoint Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Checkpoint Therapeutics's current stock value. Our valuation model uses many indicators to compare Checkpoint Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Checkpoint Therapeutics competition to find correlations between indicators driving Checkpoint Therapeutics's intrinsic value. More Info.
Checkpoint Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Checkpoint Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Checkpoint Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Checkpoint Therapeutics Systematic Risk
Checkpoint Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Checkpoint Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Checkpoint Therapeutics correlated with the market. If Beta is less than 0 Checkpoint Therapeutics generally moves in the opposite direction as compared to the market. If Checkpoint Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Checkpoint Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Checkpoint Therapeutics is generally in the same direction as the market. If Beta > 1 Checkpoint Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Checkpoint Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Checkpoint Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Checkpoint Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.0124
At this time, Checkpoint Therapeutics' Price Earnings To Growth Ratio is comparatively stable compared to the past year.
Checkpoint Therapeutics November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Checkpoint Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Checkpoint Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Checkpoint Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Checkpoint Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Checkpoint Therapeutics's daily price indicators and compare them against related drivers.
When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.